Home Icon

Loading, Please Wait...

Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update

1188 Days ago

SEATTLE, March 28, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced year end 2018 financial results and provided an update on recent company developments.

Steven C. Quay, M.D., Ph.D., Atossa Genetics’ President and CEO commented, "The end of 2018 marked two important milestones for Atossa. We completed the enrollment of our Phase 2 trial for topical Endoxifen in women with mammographic dense breasts. In addition, we received our first allowance by the FDA to provide Endoxifen through the federal “Expanded Access” program for a breast cancer patient prior to her surgery. We received a second allowance in March 2019 for this patient to continue treatment post-surgery. In the meantime, we continue to make great progress with our clinical programs and look forward to completing the dosing in the topical Endoxifen MBD trial in April and announcing preliminary results in the second quarter 2019."

Recent Corporate Developments 

  • Atossa's important recent developments include the following:

  • March 2019 - FDA approval of oral Endoxifen for "Expanded Access" as post-mastectomy treatment for a U.S. breast cancer patient

  • March 2019 – Atossa received $11.3 million from the exercise of warrants that were previously outstanding

  • February 2019 - Update from "Expanded Access" program for the U.S. breast cancer patient taking oral Endoxifen prior to surgery showing sizeable reduction in cancer cell biological activity with no safety or tolerability issues

  • February 2019 – Atossa provided breast cancer prevention recommendations to the United States Preventative Services Task Force

  • January 2019 – Successfully completed and provided final results from male Phase 1 study of topical Endoxifen; no clinically significant safety nor tolerability issues and acceptable pharmacokinetics

  • December 2018 - FDA approval of Endoxifen for "Expanded Access" as preoperative systemic endocrine therapy for a U.S. breast cancer patient

  • October 2018 - Completed enrollment in Phase 2 study of topical Endoxifen to treat mammographic breast density.

2018 Financial Results 

For the year end December 31, 2018 and 2017, we had no revenue and no associated cost of revenue.

Total operating expenses were $11,434,000 for the year ended December 31, 2018, which is an increase of $3,785,000 or 49 percent, from the year ended December 31, 2017. Operating expenses for 2018 consisted of research and development (R&D) expenses of $4,210,000 and general and administrative (G&A) expenses of $7,224,000. Operating expenses for 2017 consisted of R&D expenses of $2,328,000, G&A expenses of $4,859,000 and impairment of our Acueity intangible assets of $462,000.

R&D expenses for the year ended December 31, 2018, were $4,210,000, an increase of $1,882,000 or 81 percent from total R&D expenses in 2017 of $2,328,000. The increase in R&D expense is attributed to manufacturing and clinical trials associated with our Endoxifen program, salaries, and stock-based compensation. Our R&D expenses have increased because we commenced two Phase 2 studies of our proprietary Endoxifen during the year ended December 31, 2018. There were no Phase 2 studies of Endoxifen in 2017. Stock-based compensation expense also increased approximately $627,000 in 2018 as compared to 2017. We expect our R&D expenses to increase throughout 2019 as we commence additional Phase 2 clinical studies of Endoxifen, continue the clinical trial of fulvestrant administered via our microcatheters and continue the development of other indications and therapeutics, including CAR-T and immunotherapies administered via our intraductal technology.

G&A expenses were $7,224,000 for the year ended December 31, 2018, an increase of $2,365,000, or 49 percent from the total G&A expenses for the year ended December 31, 2017, of $4,859,000. G&A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses. The increase in G&A expenses for year ended December 31, 2018, is mainly attributed to an increase in stock-based compensation expense of approximately $1,049,000, payroll expenses resulting from salary increases, one-time bonus payments of $350,000 and increased legal and professional consulting expenses of approximately $600,000 over the prior year.

As of December 31, 2018, the company had cash, cash equivalents and restricted cash of $10.5 million and in March 2019 received $11.3 million in additional cash from the exercise of previously outstanding warrants.

About Atossa Genetics 

Atossa Genetics Inc., is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa's drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form10-K and 10-Q,each as amended and supplemented from time to time.

Atossa Genetics Company Contact:
Atossa Genetics Inc.
Kyle Guse CFO and General Counsel
Office: 866 893-4927

Investor Relations Contact:
Scott Gordon
Core IR
377 Oak Street
Concourse 2
Garden City, NY 11530
Office:(516) 222-2560

Source: Atossa Genetics Inc.



  As of December 31,  
Assets 2018     2017  
Current assets              
Cash and cash equivalents $ 10,380,493     $ 7,217,469  
Restricted cash   110,000       55,000  
Prepaid expenses   509,833       250,944  
Research and development tax rebate receivable   518,098       358,277  
Other current assets   30,942       16,344  
Total current assets   11,549,366       7,898,034  
Furniture and equipment, net   54,487       11,467  
Intangible assets, net   99,375       75,686  
Other assets   17,218       178,907  
Total Assets $ 11,720,446     $ 8,164,094  
Liabilities and Stockholders' Equity              
Current liabilities              
Accounts payable $ 353,328     $ 334,901  
Accrued expenses   177,074       90,105  
Payroll liabilities   935,070       784,867  
Stock-based compensation liability   1,410,025          
Other current liabilities   39,939       15,534  
Total Current Liabilities   2,915,436       1,225,407  
Commitments and contingencies              
Stockholders' equity              
Preferred stock - $0.001 par value; 10,000,000 shares authorized, consisting of Series A convertible preferred stock- $0.001 par value; 4,000 shares authorized, and 0 shares outstanding as of December 31, 2018 and December 31, 2017; Series B convertible preferred stock- $0.001 par value; 25,000 and 0 shares authorized, and 2,379 and 0 shares issued and outstanding as of December 31, 2018 and December 31, 2017, respectively   2          
Additional paid-in capital - Series B convertible preferred stock   2,378,997          
Common stock - $0.18 par value; 175,000,000 shares authorized, and 5,846,552 and 2,651,952 shares issued and outstanding, as of December 31, 2018 and December 31, 2017, respectively   1,052,372       477,342  
Additional paid-in capital   82,204,902       71,887,674  
Accumulated deficit   (76,831,263 )     (65,426,329 )
Total Stockholders' Equity   8,805,010       6,938,687  
Total Liabilities and Stockholders' Equity $ 11,720,446     $ 8,164,094  



  For the Years Ended December 31,  
  2018     2017  
Operating Expenses              
Research and development $ 4,209,981     $ 2,328,087  
General and administrative   7,224,252       4,859,369  
Impairment of intangible assets           461,715  
Total operating expenses   11,434,233       7,649,171  
Operating loss   (11,434,233 )     (7,649,171 )
Change in fair value of common stock warrants           (280,747 )
Warrant financing expense           (192,817 )
Other income   29,299       154  
Loss before income taxes   (11,404,934 )     (8,122,581 )
Income taxes              
Net loss $ (11,404,934 )   $ (8,122,581 )
Deemed dividend attributable to preferred stock   (11,479,308 )     (2,568,132 )
Net loss applicable to common shareholders $ (22,884,242 )   $ (10,690,713 )
Loss per common share - basic and diluted $ (5.50 )   $ (10.97 )
Weighted average shares outstanding - basic and diluted   4,157,746       974,773  

We Are Diffrent
Is your business listed correctly on America’s largest city directory network of 1,000 portals? Find your City Portal